Oesophageal cancer ranks as one of the most common malignancy in China and worldwide. Although genome-wide association studies and molecular biology studies aim to elucidate the driver molecules in oesophageal cancer progression, the detailed mechanisms remain to be identified. Interestingly, RNF168 (RING finger protein 168) shows a high frequency of gene amplification in oesophageal cancer from TCGA database. Here, we report an important function for RNF168 protein in supporting oesophageal cancer growth and invasion by stabilizing STAT1 protein.
Funding information
The project was supported by the National Science Foundation of China (No. U1704169, Xiumin Li), the project of Science and Technology Department of Henan Province (182102310126, Xiumin Li) and the 863 project of National Science and Technology Department (SQ2015AA0202183, Lidong Wang). The study is funded by graduate innovative practice base for clinical medicine of Xinxiang Medical University.
| INTRODUCTION
Oesophageal cancer ranks no. 8 in malignancy incidence worldwide.
There are around 500 000 diagnosed oesophageal cancer patients worldwide, 1 while 60% of newly diagnosed cases are in China (477 900 cases). 2 However, oesophageal squamous cell carcinoma is the major subtype in China, while oesophageal adenocarcinoma is the major subtype in western countries. Several environmental factors, such as smoking, hot drinks and alcohol, were found for oesophageal carcinoma. 3 Besides, whole genomic sequencing revealed high rate of genetic events, including mutation and amplification, clustered in several important pathways such as proliferation, apoptosis and DNA repair control signalling. 4 However, as a lack of genetic animal models in oesophageal cancer, the detailed carcinogenic mechanism and pathologic process are poorly understood.
The JAK-STAT signalling (Janus kinase-Signal transducer and activator of transcription proteins) is proved to involve in the process of immunity, development and human cancers. 5 When JAK-STAT signalling is activated, the ligands cause the dimerization of receptors, trans-phosphorylation effect on JAK and subsequently promote STATs phosphorylation. The activated STATs form dimers, move from cytoplasm to the nuclear and promote the transcription of certain target genes. 6 JAK-STAT signalling was proved to involve in several human cancers, including oesophageal cancer. For example, the activation of JAK-STAT via IL6 could promote oesophageal cancer cell survival in paracrine manner. 7 EGFR signalling could also trans-activate JAK-STAT and promote oesophageal cancer cell migration. 8 Besides, the ligands activation and cross-talk with other signalling, little is known about the potential mechanisms and insights into novel components of JAK-STAT signalling in dealing with oesophageal cancer progression.
There are about 700 of putative E3 ligases in humans, while the RING (Really Interesting New Gene) finger protein family attracted the research attention for the E3 ligase scientists due the non-degradative ubiquitination function and modulation in chromatin structure.
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RNF168 (RING finger protein 168) was firstly characterized in 2009 as a novel ubiquitin interaction protein. 10 Further studies demonstrated that RNF168 localizes in the nuclear and plays an essential role of ubiquitination in DNA damage response (DDR). [11] [12] [13] In several DDR process, RNF168 locates at DNA repair sites and promotes mono-ubiquitination of H2A/H2AX at K13-15 to drive DNA repair complex formation.
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Previous studies have shown that RNF168 could participate in chemotherapy resistance in a group of malignancies. 14 In our analysis, the public cancer database shows RNF168 has gene amplification in oesophageal cancer patients, which tends to correlate with poor overall survival. The current study reveals the function of RNF168 in promoting JAK-STAT signalling in oesophageal cancer progression.
| MATERIALS AND METHODS

| Cell culture
NEC and EC109 oesophageal squamous cancer cells were acquired from previous study. 15 
| Plasmids
Flag-STAT1 and MYC-RNF168 plasmids were acquired from the Origene Company (Beijing, China) and were described in the previous study. 
| RNA extraction and qPCR analysis
RNA extraction process was described in the previous study. 17 36B4 was utilized for internal control. Primer sequences for qPCR are provided in Table 1 . 
| Co-immunoprecipitation
Co-immunoprecipitation experiment was described in previous study. 19 Mouse Ig G was used to pre-clear the unspecific protein binding. Cell lysates were pre-cleared for 2 hours and subsequently incubated overnight with RNF168 mouse antibody (SC-101125), while mouse IgG was used as negative control. The lysis were washed and analysed by immuno-blot with STAT1 antibody (9172).
| Protein stability assays
The STAT1 protein stability was determined between siControl and siRNF168 group in NEC cells. After 24 hours of siRNA transfection, cells were treated with cycloheximide (100 μmol/L) at indicated time points. Samples were analysed by immune-blot for STAT1 protein level.
| Wound healing assay
NEC cells were used for wound healing assay. Cells were transfected with RNF168 siRNA and siControl. After 24 hours, cells were treated with trypsin and seeded into six-well plate with 1% FBS with 100% confluence. The yellow tip was applied for making a straight line. The distance was determined at indicated time points. Percentage wound recovery was calculated as: [1−(Width of the wound at a given time/width of the wound at t = 0)] × 100%.
| Trans-well invasion assay
The transwell invasion assay was performed with two-chamber plates (#3422; Corning, Shanghai, China). For the transwell assay, 
| Analysis of protein ubiquitination
One million HEK293 cells were seeded into 10 cm plate. After 
| RNA sequence analysis
The whole genomic expression profiling analysis was based on RNA sequencing platform from BGI (Beijing Genomic Institute). The RNA sequence data are deposited in the Gene Expression Omnibus (GEO) database (assessing number: GSE118532). Differentially expressed genes was extracted for analysis (P value < 0.01 together with fold change >2) by Ingenuity Pathway Analysis. nucleus in NEC cells ( Figure 1A) . The cytoplasmic and nucleus separation assay shows that RNF168 is mostly localized in the nuclear in NEC cells ( Figure 1B) . The TCGA data (The Cancer Genome Atlas) shows that RNF168 gene is amplified in 25% of oesophageal cancer samples ( Figure 1C ). Through the survival analysis from TCGA database, we observe that RNF168 gene amplification is correlated with poor overall survival in oesophageal cancer patients (http://www.cbioportal.org/ study?id=esca_tcga#summary), which may indicate the involvement of RNF168 in oesophageal cancer progression ( Figure 1D ).
| Statistics
| RNF168 knocking down inhibits cell proliferation and invasion in oesophageal cancer cells
In order to investigate RNF168 function in oesophageal cancer, we deplete RNF168 expression by two individual siRNAs (Figure 2A ).
RNF168 depletion via two independent siRNAs significantly inhibits cell growth in both NEC and EC109 cells by WST-1 assay ( Figure 2B,C) . Besides, trans-well assays indicate RN168 depletion significantly inhibits cell migration capacity in both NEC and EC 109 cells ( Figure 2D,E, Fig. S1A ). In parallel, the wound-healing assay shows RNF168 depletion significantly decreases oesophageal cancer cell migration capability ( Figure 2F ,G). All these experiments indicate that RNF168 is essential for oesophageal cancer cell progression.
| RNF168 depletion decreases STAT1 protein level and JAK-STAT target genes in oesophageal cancer cells
To investigate the function of RNF168 in oesophageal cancer cells in an unbiased approach, we carry out the whole genomic profiling F I G U R E 1 RNF168 has high frequency of gene amplification in oesophageal cancer and tends to correlate with poor prognosis in oesophageal cancer patients. (A) NEC cells cultured on sterile glass cover slips were fixed with 4% formaldehyde for 10 min. Then the cells were incubated in permeabilization buffer (0.3% Triton X100, in phosphate buffered saline [PBS]) for 10 min. Ten percent donkey serum was added to suppress nonspecific antibody binding at room temperature for 30 min and primary antibodies were incubated overnight at 4°. Fluorochrome-conjugated secondary antibodies were added after wash in a dark chamber at room temperature. The slides were washed with PBS and mounted using mounting solution containing DAPI. Finally, slides were visualized with a NIKON80i fluorescent microscope. The antibodies were used as follows: anti-RNF168 (SC-101125, santa cruz); anti-STAT1 (9172, Cell Signalling Technology). (B) RNF168 is mainly localized in the nuclear. The subcellular protein fractionation kit (Thermo Scientific, 78840) was used for cytoplasm and nuclear separation. Tubulin and Lambin B1 were used for cytoplasm and nuclear control. (C, D) RNF168 has gene amplification in 25% of esophageal cancer patients. The TCGA database was used to extract the gene expression data. RNF168 gene amplification tends to correlate with poor overall survival in esophageal cancer patients 
| RNF168 associates with STAT1 in the nuclear and increases STAT1 protein stability
Since RNF168 is a putative E3 ligase, we infer that RNF168 might regulate STAT1 through regulating protein stability. Immuno-precipitation
shows that RNF168 associates with STAT1 in oesophageal cancer cells ( Figure 4A ). Nuclear-cytoplasm separation based Immuno-precipitation
shows that RNF168 associates with STAT1 in the nucleus ( Figure 4B ).
With the treatment of proteasome inhibitor MG132, the stabilized effect on STAT1 by RNF168 could be rescued by MG132, which indicates F I G U R E 2 RNF168 depletion inhibits cell proliferation and invasion in oesophageal cancer cells. (A) RNF168 depletion effect by two different siRNA oligos. NEC cell were transfected with siRNF168 or siControl. After 48 h, RNF168 mRNA levels are determined by real-time PCR with 36B4 as internal control. (B, C) The WST-1 assay was used to determine the cellular metabolic activity at indicated time points after transfection. NEC and EC109 cells were transfected with siRNF168 and siControl. After 24 h, cells were seeded into 96-well plates. These experiments were done in triplicates. All values are mean ± SD (n = 3, *P < 0.05; **P < 0.01, ***P < 0.001). (D, E) Transwell invasion assay of NEC cells transfected with indicated RNF168 siRNA. The cell number is counted and data are presented as ±SD. **, P < 0.01, ***, P < 0.001 (Student's t test). (F, G) Wound healing assay of NEC transfected with the indicated siRNA. Quantification of wound closure at the indicated time points. Data are presented as ±SD. **, P < 0.01, ***, P < 0.001 (Student's t test)
RNF168 modulates STAT1 stability ( Figure 4C ). Up on inhibition of protein synthesis by cycloheximide, the presence of RNF168 significantly increases the half-life of STAT1 protein in NEC cells ( Figure 4D ). With the treatment of proteasome inhibitor MG132, we observe that the expected poly-ubiquitin chains of STAT1 in the presence of RNF168 is significantly decreased ( Figure 4E ). These experiments show that RNF168 modulates STAT1 via increasing protein stability.
| DISCUSSION
In the study, we show that the E3 ubiquitin ligase RNF168 promotes oesophageal cancer cell proliferation and invasion, possibly via activating JAK-STAT signalling. Besides, we also observe that RNF168 gene is amplified in 25% of oesophageal cancer patients and tends to relate with shorter overall survival time. The unbiased RNA sequencing assay shows that RNF168 is required for JAK-STAT signalling activity, while the mechanistic study shows that RNF168 associates with STAT1 in the nuclear, stabilizes STAT1 protein and inhibits its poly-ubiquitination. This study provides a novel mechanism that RNF168 modulates JAK-STAT signalling via regulating STAT1 protein stability in oesophageal cancer. On the basis of these knowledge, we propose that selective modulation of RNF168-STAT1 interaction could be a promising strategy to inhibit oesophageal cancer proliferation and invasion ( Figure 4F ).
F I G U R E 3 RNF168 depletion decreases STAT1 protein level and JAK-STAT target genes in esophageal cancer cells. (A) Top 10 signalling pathways significantly decreased by RNF168 depletion in NEC cells. The pathway-enrichment analysis was used by the threshold P < 0.001 and fold change >2 to derive regulated genes. RNF168 was depleted by siRNA (mix of siRNF168 #1 and siRNF168 #2) or treated with siControl. After 48 h, the whole mRNA was extracted for RNA sequence analysis. The siControl and siRNF168 were done in triplicates. B: The heat-map graph shows the JAK-STAT target genes, which is significantly decreased by RNF168 depletion in NEC cells. The significantly regulated genes were overlapped with publish JAK-STAT target gene data. (C, D) RNF168 depletion effect on STAT1 protein level by two different siRNA oligos. NEC and EC109 cells were transfected with siRNF168 or siControl. After 48 h, RNF168 and STAT1 protein levels were determined by Western blot analysis. Actin was used as internal control. (E, F) RNF168 depletion decreases STAT1 target genes using two different siRNA oligos. NEC and EC109 cells were transfected with siRNF168 or siControl. After 48 h, cells, total RNA was prepared and the expression of the endogenous STAT1 target genes, IRF1, IRF9 and IFITM1 were determined by qPCR. Shown are the results from three experiments. *P < 0.05; **P < 0.01; ***P < 0.001 for target gene expression comparison and RNF31 were shown to promote oestrogen receptor alpha protein stability via facilitating ER alpha mono-ubiquitination. 27, 29, 30 RNF168 as a family of RING finger proteins, was firstly discovered as an ubiquitin-binding domain protein. 10 Further studies demonstrated that RNF168 plays an essential role of ubiquitination modification in DDR. [11] [12] [13] In several DNA damage process, RNF168 is recruited to DNA damage foci and promotes mono-ubiquitination of H2A/H2AX at K13-15 to facilitate the formation of DNA repair complex. 11 Previous studies showed that RNF168 could participate in chemotherapy resistance in various type of cancers. 14 Interestingly, RNF168 is highly amplified in oesophageal cancer patients, which lead our interests to dig into the mechanisms. Depletion of RNF168 significantly hampers the proliferation and invasion capacity in oesophageal cancer cells. We further examine the role of RNF168 in STAT1 and its function. RNF168 is shown to associate with STAT1 protein and prolong its stability. In all, our study reveals an important cancer regulation mechanism between RNF168 and JAK-STAT signalling, which indicates modulation of RNF168 protein could be an approach in inhibiting oesophageal cancer progression.
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